(See the editorial commentary by Furrer on pages 830-1.)
American patients in the contemporary ART era, and the CD4 + Tcell counts at which they occur, provides important data for informing opportunistic illness screening, prophylaxis, and management guidelines [16, 26] , and other aspects of HIV care and treatment [27] to reduce OI-associated mortality and morbidity [10, 25] . It is of particular interest and epidemiologic value to characterize the rates of first OIs among patients who have no history of prior AIDS-defining clinical events, not only because such patients compose a well-defined study population, but also because, on average, they better represent the leading edge of the HIV epidemic, namely, contemporary patients with more-recent HIV infections and less extensive treatment histories.
In this report, we focus on incident AIDS-defining infections in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD); rates of AIDS-defining malignancies have been described separately [28] . We sought to assess whether incidence rates of first OIs have continued to decline or have stabilized over the last decade among such HIV-infected patients in care and to describe risk factors for and the epidemiology of these OIs in the recent ART era.
METHODS

Study Population
The NA-ACCORD is the largest collaboration of longitudinal HIV cohort studies in North America and has compiled data from >100 clinical sites in the United States and Canada [12, 29] . Briefly, at scheduled intervals, participating HIV cohorts submit data regarding enrolled participants' demographic characteristics, vital status, prescribed antiretrovirals, clinical diagnoses, and dates and results of laboratory tests including HIV load and CD4 + T-cell count. These clinical data are obtained from routine chart abstractions or scheduled study visits, depending on the cohort. Among clinical cohorts, only persons with ≥2 clinical visits within 12 months are enrolled into the NA-ACCORD. Death is ascertained by each contributing cohort by using a variety of methods, including the National Death Index, the Social Security Death Index, and state, provincial, and local sources, such as death certificates and electronic medical records. NA-ACCORD data undergo extensive quality control for completeness and accuracy per a standardized protocol before they are combined into harmonized data files at the NA-ACCORD's Data Management Center (University of Washington, Seattle, Washington). The data are reviewed again, organized into analytic files, and analyzed at the NA-ACCORD Epidemiology and Biostatistics Core (Johns Hopkins University, Baltimore, Maryland). The human subjects research activities of the NA-ACCORD and each of the participating cohort studies have been reviewed and approved by their respective local institutional review boards and by the Johns Hopkins School of Medicine. We analyzed data from HIV-infected persons followed in 16 participating cohorts in NA-ACCORD in the United States and Canada, listed at the end of the text, during 2000-2010; each cohort agreed to participate and had available OI data for this analysis. Because the protocols for collection and validation of OIs varied across participating cohorts, if a given cohort contributed no OI events of a specific type (eg, cryptococcal meningitis and disseminated coccidioidomycosis) during any one of the 3 analysis periods (2000-2003, 2004-2007, and 2008-2010) , that cohort was excluded entirely from analyses of that specific OI during that particular period, to avoid underestimating OI incidence rates. Sensitivity analyses without this exclusion were performed (see below). We further restricted analyses to persons who had no history of any clinical AIDS events at the start of their observation but imposed no restrictions on their CD4 + T-cell count, HIV load, or prescription of ART at baseline. We analyzed data from 1 January 2000 or the date the participating cohort began contributing data (cohort entry date), whichever came later. The start of observation for each patient (baseline) was the later of the patient's enrollment date in the participating cohort or 1 January 2000. The end of follow-up for each patient was the earliest of the following: the patient's last CD4 + T-cell count or last HIV load date plus 6 months, the date of the event being analyzed (ie, either the first occurrence of any OI diagnosis or the first occurrence of a specific OI of interest, regardless of prior occurrence of other OIs), the date of death, or the end of the study period (31 December 2010). . The participating cohorts relied on standard definitions for ART and for prophylaxis to prevent Pneumocystis pneumonia (PCP) and disseminated Mycobacterium avium complex (MAC) infection [26, 27] . We studied all OIs listed in the Centers for Disease Control (CDC) 2014 surveillance case definition for HIV infection [18, 19, 26] , with a few exceptions, as noted in the Appendix. OI events were defined solely on the basis of diagnoses recorded by the participating cohorts. The CD4 + T-cell counts and HIV loads at the beginning of each period were those measured nearest to the start of observation in the period (from 6 months before up to 6 months after). We also examined the CD4 + T-cell count and HIV load closest to incident OI diagnoses (from 6 months before up to 3 months after). Finally, the CD4 + T-cell count and HIV load at ART initiation were the nearest measurements from 6 months before through the date of ART initiation.
Statistical Methods
We calculated incidence rates of OI diagnoses per 100 personyears with 95% Poisson confidence intervals (CIs) for the first occurrence of any OI and for the first occurrence of select OIs that were uniformly ascertained in the participating cohorts. Incidence rate estimates for selected OIs were calculated by ignoring the occurrence of other OIs prior to the first occurrence of the OI of interest. For each OI, we summed the total observation time across participating patients from the start of observation to the end of follow-up for each patient. The incidence of individual OIs was estimated on an event-by-event basis. For example, in the analyses of incident tuberculosis, if during follow-up a person received a diagnosis of another OI, such as candidiasis, before receiving a diagnosis of tuberculosis, they still contributed all available observation time up to the date of tuberculosis diagnosis to the tuberculosis incidence rate calculation. Tests of temporal trends in OI rates were assessed using Poisson regression models. We also quantified the incidence rates of any OI in a subset of persons who initiated ART during 2000-2010. We estimated the time to any first OI with the Kaplan-Meier method; as a sensitivity analysis, we accounted for the competing risk of death [30, 31] , thus providing an overall estimate of the cumulative incidence of the OI event occurring prior to death according to calendar period or CD4 + T-cell count at ART initiation.
Using Poisson regression, we further explored the clinical and sociodemographic risk factors for select high-incidence OIs, adjusting for the following factors at the start of observation in each calendar period: age, sex, race/ethnicity, CD4 + T-cell count, HIV load, and cohort. A patient may have contributed observation time to multiple calendar periods. We explored additional modeling strategies by including a variable for whether or not a patient used ART at the start of observation for each calendar period, but we omitted this variable from the final models because of its strong dependence on CD4 + T-cell count at the start of the period and calendar period. We report incidence rate ratios (IRRs) and 95% CIs. We performed analyses using SAS, version 9.3 (Cary, North Carolina).
RESULTS
We identified 80 278 HIV-infected persons followed in 16 participating cohorts in NA-ACCORD in the United States and Canada during 2000-2010. After excluding 16 737 persons (21%) with any history of documented AIDS-defining conditions at baseline (see the Appendix for details), we analyzed incident OIs among the remaining 63 541 persons, regardless of their baseline immunologic status or ART use.
Persons at Risk for Development of OIs
Of persons studied, median age at baseline was 40 years (interquartile range, 34-47 years), 78% were men, 40% were white, 37% were black, 41% were men who have sex with men (MSM), 19% were persons who had injection drug use (IDU) as an HIV risk factor; and 12% were Canadian (Table 1) . Median CD4 + T-cell count at baseline was 360 cells/mm 3 (IQR, 196-557 cells/mm 3 ), about one third had a baseline HIV load of <500 copies/mL, and 43% had any documented ART prescription at the start of observation for this analysis. The subset of persons who were antiretroviral naive at baseline and initiated ART sometime during their observation had largely similar demographic characteristics to those of all persons in our study population (Table 1) . During 2000-2010, 63 541 persons contributed 261 573 person-years of observation, and 5836 developed at least 1 OI. The 27 500 persons who started ART during the period of analysis Table 2 ). These decreases coincided with temporal improvements in clinical status and care of the entire study population: increases in the percentage of observation time during which ART was received, median CD4 + T-cell counts, and frequency with HIV loads of <500 copies/mL (P < .001 for comparisons; Table 2 ). The incidence rates of key high-frequency OIs declined significantly over time (P < .05; Figure 1) , as did the rates of most other OIs (Table 3) , except for the less-frequent OIs, such as isosporiasis, coccidioidomycosis, and histoplasmosis, as well as toxoplasmosis and CMV infection, for which no significant declines were noted (P ≥ .05). During 2008-2010, the leading OIs included PCP, esophageal candidiasis, and disseminated MAC or M. kansasii infection. In sensitivity analyses of OI incidence rates that included person-years of observation for cohorts that did not report any OIs of a given type during the calendar period(s), we found somewhat lower rates for some OIs (Supplementary Table 1 ), but the overall first OI rates and the statistical inferences regarding temporal trends were similar.
Risk Factors for OIs
In multivariable Poisson regression models (Supplementary . For most individual OIs, the incidence rates were consistently and markedly increased among persons with low CD4 + T-cell counts and elevated HIV loads, and some associations with sex, race/ethnicity, and HIV risk status were noted (Supplementary Table 2 ).
Occurrence of OIs Among Persons Starting ART
Among a subset of persons initiating ART, the incidence rate of any first OI declined over the 3 calendar periods (Table 2 ) in a similar pattern as for all persons studied. Overall, by 2 years after initiating ART, approximately 4% of persons experienced a first OI, and that percentage was 3% for persons starting ART in Figure 1) .
Trends in CD4 + T-Cell Counts at OI Diagnosis
The CD4 + T-cell count was available for 5465 of 5836 OI diagnoses (94%) and was measured a median of 2 days before the OI diagnosis (IQR, 18 days before to 7 days after the OI diagnosis). A substantial percentage of OIs occurred among patients with CD4 + T-cell counts of ≥200 cells/mm . Notably, most OIs occurred among persons prescribed ART, a substantial fraction of whom had virological suppression (<500 copies/mL) proximal to OI diagnosis ( Figure 3) . Although it is possible that some of these events were consistent with immune reconstitution inflammatory syndrome [32, 33] , we observed no marked increase in risk of any first OI diagnosis within 6 months of ART initiation (Figure 2A ).
DISCUSSION
In our large and demographically diverse cohort of HIV-infected persons in care in the United States and Canada, we observed persistent reductions in incidence rates of first OIs during 2000-2010, which coincided with the improvements in viral suppression and immune status of our study population receiving increasingly potent and tolerable newer ART regimens [12] . We found that, on average, among contemporary North American patients with no history of an AIDS-defining event, fewer than 2 in 100 developed any OI per year. Among a subset of persons starting ART during 2008-2010, the probability of developing a new OI within the next 2 years was about 7% when the initial CD4 + T-cell count was <200 cells/mm 3 and 1% when the initial CD4 + T-cell count was ≥500 cells/mm 3 . Although direct comparisons of our observed OI rates to those reported from other cohorts are not appropriate because of multiple cross-cohort differences, including degree of immunosuppression and differences in analytic methods, our absolute OI incidence rates were generally of the same magnitude as in other studies of OIs during the ART era [3] [4] [5] . Higher HIV loads and lower CD4 + T-cell counts remained associated with OIs among patients, corroborating earlier analyses [1, 21, 24, 34] . Since most persons in our analyses were ART recipients, these findings could reflect patients with more-recent ART initiation, suboptimal responses to ART, or medication nonadherence. In addition, as in prior studies, we found that certain demographic factors increased the risk for specific OIs [3, 5, 35, 36] , including older age, male sex, and HIV transmission risk behavior (eg, IDU and male-male sex for a variety of opportunistic infections [5, 35] ). A considerable variability in CD4 + T-cell counts at diagnosis of OIs has been documented before and after introduction of ART, with some patients experiencing OIs at relatively high CD4 + T-cell counts [3, 5, 24] . Two principal hypotheses exist to explain observed trends [1, 37, 38] . First, the increase in median CD4 + T-cell count at diagnosis, for the few OI events that still occur, likely reflects the increased CD4 + T-cell counts of the entire NA-ACCORD population followed after introduction of ART (Table 1) . Second, ART-associated immune restoration is functionally incomplete, particularly among persons who had experienced profound CD4 + T-cell depletion, resulting in OI occurrence at higher CD4 + T-cell counts.
In this analysis, we investigated incidence rates for the first occurrence of any OI and of individual OIs. It is difficult to accurately assess the prevalence or total burden of OIs in a population at any point in time, for at least 2 reasons: (1) some viral OIs are chronic, and their historical documentation since the date of initial onset is likely incompletely recorded across many participating cohorts in NA-ACCORD; and (2) some OIs may occur more than once, and the dates of their onset, resolution, and recurrence may not be well recorded. Our approach to focus on first incident OIs among patients without any preexisting OIs (ie, no clinical AIDS) as per their available medical history results in our study population being, on average, more reflective of patients with less advanced HIV disease and more-recently diagnosed HIV infection; we also examined OI rates among persons newly starting ART. Our study has several limitations. We relied on the standardized study protocols of 16 participating cohorts for ascertaining OIs without reviewing original medical records to conduct centralized NA-ACCORD event validation. Although most OIs present acutely and thereby bring affected patients into clinical care, some OIs might have gone undetected because of presentation and care provided outside of the participating NA-ACCORD facilities or subclinical presentation or incomplete screening (eg, tuberculosis); we do not suspect this possible underascertainment to differ over time, but it could result in underestimation of OI incidence. To guard against underreporting bias, for each analysis period we excluded from incidence calculations any cohort reporting no OI events of that type in the period (eg, this occurred when a cohort could report all candidiasis cases without differentiating esophageal candidiasis); we chose this approach because we believed that underascertainment of OIs posed a greater threat to the validity of our results than potentially inflating OI rates (by removing observation time when no events were recorded). In sensitivity analyses, which considered all available person-time whether or not a cohort reported any OI events of a given type, the individual OI rates were somewhat lower, but the inferences regarding decreasing or level trends in incidence of OIs over time were similar (Supplementary Table 1 ). Overestimation of first OI incidence rates could have also resulted from inadvertent inclusion of patients with preexisting OI histories that were not documented in available medical records and because some patients may have had latent infections or bacterial colonization, as well as immune-compromising conditions beyond HIV infection, that could lead to OI misdiagnoses [39] . Conversely, our report excludes some OIs, chiefly recurrent bacterial pneumonia, because neither recurrence nor differentiation between bacterial and viral pneumonia was systematically documented in most cohorts; thus, our overall incidence rate of any first OI may be lower than had these diagnoses been included. We assessed temporal trends and use of ART in a descriptive, ecological fashion and did not quantify the precise reductions in incidence of given OIs attributable to ART use, which was not the primary goal of our analysis and would have required accounting for confounding by indication [40] . Finally, ascertainment of ART prescriptions, particularly before and at enrollment into participating NA-ACCORD cohorts, may be incomplete, depending on the available patient medical records.
In conclusion, in our large and diverse cohort of HIV-infected patients in North America, rates of first OIs in the ART era have continued to decline during 2000-2010. OIs that predominated in the pre-ART period in prior US-based analyses [1, 4, 35] , such as PCP and esophageal candidiasis, have remained prominent in the contemporary ART period. A significant minority of patients have OIs diagnosed at higher-than-expected CD4 + T-cell counts and possibly while experiencing virological suppression, highlighting that healthcare providers need to remain vigilant for incident opportunistic illnesses in all HIV-infected patients and reduce OI-associated morbidity and mortality. Early HIV diagnosis and prompt linkage of HIV-infected patients to care with immediate offer of ART [27, 41] are also key to achieve further gains in OI prevention.
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